{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:01:24Z","timestamp":1781262084826,"version":"3.54.1"},"reference-count":73,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Advanced-stage classic Hodgkin lymphoma (cHL) represents one of the major success stories in modern oncology, with long-term survival now exceeding 80% for most patients. In this review, we examine the evolution of frontline therapy for advanced-stage cHL, tracing the transition from empiric combination chemotherapy to contemporary, biologically informed treatment strategies. We begin by revisiting the early development of multiagent chemotherapy regimens, including MOPP and ABVD. These regimens established, for the first time, that advanced lymphoma could be cured with systemic therapy. We then discuss efforts to improve outcomes through treatment intensification, which culminated in the development of BEACOPP-based approaches that improved disease control at the cost of substantial acute and long-term toxicity. Subsequently, the incorporation of functional imaging ushered in the era of PET-adapted therapy, enabling dynamic treatment modification based on early response and providing a framework to better balance efficacy with toxicity reduction. Finally, we review the integration of novel agents, including brentuximab vedotin and PD-1 blockade, which have reshaped the frontline treatment landscape and further improved outcomes for high-risk patients while challenging historical chemotherapy paradigms. Collectively, the treatment history of advanced-stage cHL reflects a broader evolution in oncology: from maximizing cytotoxic intensity toward increasingly personalized strategies designed to optimize cure while minimizing long-term harm. Ongoing efforts focused on biomarker-driven risk stratification and the utilization of circulating tumor DNA are poised to further refine this balance in the coming decade.<\/jats:p>","DOI":"10.3390\/cancers18121919","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:49:51Z","timestamp":1781257791000},"page":"1919","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Therapy for Advanced-Stage Hodgkin Lymphoma"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7712-4605","authenticated-orcid":false,"given":"Varun","family":"Iyengar","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishan","family":"Patel","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3408-050X","authenticated-orcid":false,"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.6004\/jnccn.2026.0006","article-title":"Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology","volume":"24","author":"Advani","year":"2026","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_2","first-page":"10","article-title":"Cancer Statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(12)60035-X","article-title":"Hodgkin\u2019s Lymphoma in Adults","volume":"380","author":"Townsend","year":"2012","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/annonc\/13.S1.11","article-title":"Biology of Hodgkin\u2019s Lymphoma","volume":"13","author":"Schwering","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The Tumour Microenvironment in B Cell Lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-73-6-881","article-title":"Combination Chemotherapy in the Treatment of Advanced Hodgkin\u2019s Disease","volume":"73","author":"Devita","year":"1970","journal-title":"Ann. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1046\/j.1365-2141.2003.04541.x","article-title":"A Selective History of the Therapy of Hodgkin\u2019s Disease","volume":"122","author":"DeVita","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.7326\/0003-4819-92-5-587","article-title":"Curability of Advanced Hodgkin\u2019s Disease with Chemotherapy: Long-Term Follow-up of MOPP-Treated Patients at the National Cancer Institute","volume":"92","author":"Devita","year":"1980","journal-title":"Ann. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/bmj.285.6355.1612","article-title":"Gonadal Function in Hodgkin\u2019s Disease: Long-Term Follow-up of Chemotherapy","volume":"285","author":"Waxman","year":"1982","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1200\/JCO.1986.4.9.1295","article-title":"Twenty Years of MOPP Therapy for Hodgkin\u2019s Disease","volume":"4","author":"Longo","year":"1986","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/asheducation-2016.1.323","article-title":"Long-Term Risk of Second Malignancy and Cardiovascular Disease after Hodgkin Lymphoma Treatment","volume":"2016","author":"Ng","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM198801143180203","article-title":"Risk of Second Cancers after Treatment for Hodgkin\u2019s Disease","volume":"318","author":"Tucker","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","article-title":"Combination Chemotherapy of Hodgkin\u2019s Disease with Adriamycin, Bleomycin, Vinblastine, and Imidazole Carboxamide versus MOPP","volume":"36","author":"Bonadonna","year":"1975","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of Advanced Hodgkin\u2019s Disease with MOPP, ABVD, or MOPP Alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin\u2019s Disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1200\/JCO.1991.9.8.1409","article-title":"Treatment of Advanced-Stage Hodgkin\u2019s Disease: Alternating Noncrossresistant MOPP\/CABS Is Not Superior to MOPP","volume":"9","author":"Longo","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.1997.15.4.1638","article-title":"Treatment of Advanced Hodgkin\u2019s Disease with Chemotherapy\u2014Comparison of MOPP\/ABV Hybrid Regimen with Alternating Courses of MOPP and ABVD: A Report from the National Cancer Institute of Canada Clinical Trials Group","volume":"15","author":"Connors","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized Comparison of ABVD and MOPP\/ABV Hybrid for the Treatment of Advanced Hodgkin\u2019s Disease: Report of an Intergroup Trial","volume":"21","author":"Duggan","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1023\/A:1008294312741","article-title":"BEACOPP: An Intensified Chemotherapy Regimen in Advanced Hodgkin\u2019s Disease","volume":"8","author":"Diehl","year":"1997","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0025-5564(83)90066-4","article-title":"A Model for the Resistance of Tumor Cells to Cancer Chemotherapeutic Agents","volume":"65","author":"Coldman","year":"1983","journal-title":"Math. Biosci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin\u2019s Lymphoma: Results From the HD2000 Gruppo Italiano per Lo Studio Dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdu189","article-title":"ABVD (8 Cycles) versus BEACOPP (4 Escalated Cycles \u22654 Baseline): Final Results in Stage III\u2013IV Low-Risk Hodgkin Lymphoma (IPS 0\u20132) of the LYSA H34 Randomized Trial","volume":"25","author":"Mounier","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1002\/cam4.3298","article-title":"Long-term Overall Survival and Toxicities of ABVD vs BEACOPP in Advanced Hodgkin Lymphoma: A Pooled Analysis of Four Randomized Trials","volume":"9","author":"Carde","year":"2020","journal-title":"Cancer Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive Conventional Chemotherapy Compared with High-Dose Chemotherapy with Autologous Haemopoietic Stem-Cell Transplantation for Relapsed Chemosensitive Hodgkin\u2019s Disease: A Randomised Trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the First International Workshop on Interim-PET Scan in Lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin\u2019s Lymphoma: A Report From a Joint Italian-Danish Study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose\u2013Positron Emission Tomography Imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood-2018-99-113034","article-title":"Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III\/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach","volume":"132","author":"Stephens","year":"2018","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1182\/blood.V120.21.550.550","article-title":"Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses\u2014First Interim Analysis of the GITIL\/FIL HD0607 Clinical Trial","volume":"120","author":"Gallamini","year":"2012","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography\/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL\/FIL HD 0607 Trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim Positron Emission Tomography Response\u2013Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study","volume":"34","author":"Zinzani","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin\u2019s Lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.23.01177","article-title":"Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial","volume":"42","author":"Luminari","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-Adapted Treatment for Newly Diagnosed Advanced Hodgkin Lymphoma (AHL2011): A Randomised, Multicentre, Non-Inferiority, Phase 3 Study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1200\/JCO.21.01777","article-title":"Positron Emission Tomography\u2013Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study","volume":"40","author":"Casasnovas","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-Guided Treatment in Patients with Advanced-Stage Hodgkin\u2019s Lymphoma (HD18): Final Results of an Open-Label, International, Randomised Phase 3 Trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.annonc.2023.11.014","article-title":"Impact of Individualized Treatment on Recovery from Fatigue and Return to Work in Survivors of Advanced-Stage Hodgkin\u2019s Lymphoma: Results from the Randomized International GHSG HD18 Trial","volume":"35","author":"Ferdinandus","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/1078-0432.CCR-12-0290","article-title":"Brentuximab Vedotin","volume":"19","author":"Deng","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin\u2019s Lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin\u2019s Lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the Efficacy and Tolerability of PET-Guided BrECADD versus eBEACOPP in Advanced-Stage, Classical Hodgkin Lymphoma (HD21): A Randomised, Multicentre, Parallel, Open-Label, Phase 3 Trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"LBA7000","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA7000","article-title":"Tolerability and Efficacy of BrECADD versus BEACOPP in Advanced Stage Classical Hodgkin Lymphoma: GHSG HD21, a Randomized Study","volume":"42","author":"Borchmann","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative Analysis Reveals Selective 9p24.1 Amplification, Increased PD-1 Ligand Expression, and Further Induction via JAK2 in Nodular Sclerosing Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"13134","DOI":"10.1073\/pnas.0706017104","article-title":"The AP1-Dependent Secretion of Galectin-1 by Reed\u2013Sternberg Cells Fosters Immune Privilege in Classical Hodgkin Lymphoma","volume":"104","author":"Juszczynski","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The Biology of Hodgkin\u2019s Lymphoma","volume":"9","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/aol.2017.08.03","article-title":"Hodgkin Lymphoma and PD-1 Blockade: An Unfinished Story","volume":"1","author":"Merryman","year":"2017","journal-title":"Ann. Lymphoma"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for Relapsed\/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1182\/bloodadvances.2023010334","article-title":"Nivolumab for Relapsed\/Refractory Classical Hodgkin Lymphoma: 5-Year Survival from the Pivotal Phase 2 CheckMate 205 Study","volume":"7","author":"Ansell","year":"2023","journal-title":"Blood Adv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five-Year Follow-up of KEYNOTE-087: Pembrolizumab Monotherapy for Relapsed\/Refractory Classical Hodgkin Lymphoma","volume":"142","author":"Armand","year":"2023","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in Advanced-Stage Classic Hodgkin\u2019s Lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood-2025-151","article-title":"3-Year Follow-up of the S1826 Study Confirms Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma","volume":"146","author":"Herrera","year":"2025","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.2012.47.3058","article-title":"How Can Outcomes Be Improved for Older Patients With Hodgkin Lymphoma?","volume":"31","author":"Evens","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin\u2019s Lymphoma in Elderly Patients: A Comprehensive Retrospective Analysis From the German Hodgkin\u2019s Study Group","volume":"23","author":"Engert","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO-25-00204","article-title":"Nivolumab-AVD Versus Brentuximab Vedotin\u2013AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826","volume":"43","author":"Rutherford","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1200\/JCO-24-01278","article-title":"Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma","volume":"43","author":"Torka","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(25)00262-1","article-title":"Fertility in Patients with Advanced-Stage Classic Hodgkin Lymphoma Treated with BrECADD versus eBEACOPP: A Secondary Analysis of the Multicentre, Randomised, Parallel, Open-Label, Phase 3 HD21 Trial","volume":"26","author":"Ferdinandus","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1182\/blood-2023-189250","article-title":"Fertility and Gonadal Function after First-Line Treatment with Nivolumab-AVD in Hodgkin Lymphoma Patients: An Analysis from the Phase II GHSG Nivahl Trial","volume":"142","author":"Herhaus","year":"2023","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2025-1851","article-title":"Interim and End-of-Treatment FDG-PET Demonstrate Limited Ability to Predict 3-Year Progression-Free Survival with Nivolumab-AVD in First-Line Treatment of Advanced Stage Hodgkin Lymphoma: Imaging Sub-Analysis of Phase 3 S1826 Study","volume":"146","author":"Bartlett","year":"2025","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/S2352-3026(26)00068-2","article-title":"Very Early [18F]FDG-PET-Guided Targeted Therapy in Untreated Advanced-Stage Classic Hodgkin Lymphoma (EORTC-1537-COBRA): Primary Results of a Single-Arm, Multicentre, Phase 2 Trial","volume":"13","author":"Hutchings","year":"2026","journal-title":"Lancet Haematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/blood-2025-153","article-title":"Interim PET-Adapted de-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Study","volume":"146","author":"Lee","year":"2025","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating Tumor DNA Reveals Genetics, Clonal Evolution, and Residual Disease in Classical Hodgkin Lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin Lymphoma Subtypes Defined by Noninvasive Genomic Profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1182\/blood-2025-5408","article-title":"Precise-HL Trial: Personalized Reduction of Chemotherapy Intensity through Ctdna Evaluation in Advanced Hodgkin Lymphoma","volume":"146","author":"Lynch","year":"2025","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijrobp.2024.04.021","article-title":"At the Cutting Edge: Novel Agents in Hodgkin Lymphoma and the Evolving Role of Radiation Therapy","volume":"120","author":"Lo","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using Immunotherapy to Boost the Abscopal Effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/j.clml.2021.09.005","article-title":"\u2018Le Roi Est Mort, Vive Le Roi\u2019: New Roles of Radiotherapy in the Treatment of Lymphomas in Combination With Immunotherapy","volume":"22","author":"Guerini","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/1919\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:30:58Z","timestamp":1781260258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/12\/1919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":73,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18121919"],"URL":"https:\/\/doi.org\/10.3390\/cancers18121919","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]}}}